Literature DB >> 32128578

Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum.

Juthakorn Poothong1, Anita Pottekat1, Marina Siirin1, Alexandre Rosa Campos2, Adrienne W Paton3, James C Paton3, Jacqueline Lagunas-Acosta1, Zhouji Chen1, Mark Swift4, Niels Volkmann4, Dorit Hanein4, Jing Yong1, Randal J Kaufman1.   

Abstract

Hemophilia A, an X-linked bleeding disorder caused by deficiency of factor VIII (FVIII), is treated by protein replacement. Unfortunately, this regimen is costly due to the expense of producing recombinant FVIII as a consequence of its low-level secretion from mammalian host cells. FVIII expression activates the endoplasmic reticulum (ER) stress response, causes oxidative stress, and induces apoptosis. Importantly, little is known about the factors that cause protein misfolding and aggregation in metazoans. Here, we identified intrinsic and extrinsic factors that cause FVIII to form aggregates. We show that FVIII forms amyloid-like fibrils within the ER lumen upon increased FVIII synthesis or inhibition of glucose metabolism. Significantly, FVIII amyloids can be dissolved upon restoration of glucose metabolism to produce functional secreted FVIII. Two ER chaperone families and their cochaperones, immunoglobulin binding protein (BiP) and calnexin/calreticulin, promote FVIII solubility in the ER, where the former is also required for disaggregation. A short aggregation motif in the FVIII A1 domain (termed Aggron) is necessary and sufficient to seed β-sheet polymerization, and BiP binding to this Aggron prevents amyloidogenesis. Our findings provide novel insight into mechanisms that limit FVIII secretion and ER protein aggregation in general and have implication for ongoing hemophilia A gene-therapy clinical trials.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32128578      PMCID: PMC7243144          DOI: 10.1182/blood.2019002867

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  54 in total

1.  Subtilase cytotoxin activates PERK, IRE1 and ATF6 endoplasmic reticulum stress-signalling pathways.

Authors:  Jennifer J Wolfson; Kerrie L May; Cheleste M Thorpe; Dakshina M Jandhyala; James C Paton; Adrienne W Paton
Journal:  Cell Microbiol       Date:  2008-04-21       Impact factor: 3.715

2.  Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII.

Authors:  T Shahani; K Covens; R Lavend'homme; N Jazouli; E Sokal; K Peerlinck; M Jacquemin
Journal:  J Thromb Haemost       Date:  2014-01       Impact factor: 5.824

3.  Molecular cloning of a cDNA encoding human antihaemophilic factor.

Authors:  J J Toole; J L Knopf; J M Wozney; L A Sultzman; J L Buecker; D D Pittman; R J Kaufman; E Brown; C Shoemaker; E C Orr
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

4.  An X-ray crystallographic study of the binding sites of the azide inhibitor and organic substrates to ceruloplasmin, a multi-copper oxidase in the plasma.

Authors:  V N Zaitsev; I Zaitseva; M Papiz; P F Lindley
Journal:  J Biol Inorg Chem       Date:  1999-10       Impact factor: 3.358

5.  Murine coagulation factor VIII is synthesized in endothelial cells.

Authors:  Lesley A Everett; Audrey C A Cleuren; Rami N Khoriaty; David Ginsburg
Journal:  Blood       Date:  2014-04-09       Impact factor: 22.113

6.  BiP-binding sequences in HIV gp160. Implications for the binding specificity of bip.

Authors:  G Knarr; S Modrow; A Todd; M J Gething; J Buchner
Journal:  J Biol Chem       Date:  1999-10-15       Impact factor: 5.157

7.  Transplantation of endothelial cells corrects the phenotype in hemophilia A mice.

Authors:  V Kumaran; D Benten; A Follenzi; B Joseph; R Sarkar; S Gupta
Journal:  J Thromb Haemost       Date:  2005-09       Impact factor: 5.824

8.  Rapid induction of Alzheimer A beta amyloid formation by zinc.

Authors:  A I Bush; W H Pettingell; G Multhaup; M d Paradis; J P Vonsattel; J F Gusella; K Beyreuther; C L Masters; R E Tanzi
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

9.  Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells.

Authors:  R J Kaufman; L C Wasley; A J Dorner
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

10.  The molecular chaperone calnexin facilitates folding and assembly of class I histocompatibility molecules.

Authors:  A Vassilakos; M F Cohen-Doyle; P A Peterson; M R Jackson; D B Williams
Journal:  EMBO J       Date:  1996-04-01       Impact factor: 11.598

View more
  12 in total

1.  Gene Therapy for Inherited Bleeding Disorders.

Authors:  Valder R Arruda; Jesse Weber; Benjamin J Samelson-Jones
Journal:  Semin Thromb Hemost       Date:  2021-02-26       Impact factor: 4.180

Review 2.  Hemophilia gene therapy: ushering in a new treatment paradigm?

Authors:  Lindsey A George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.

Authors:  Lindsey A George; Paul E Monahan; M Elaine Eyster; Spencer K Sullivan; Margaret V Ragni; Stacy E Croteau; John E J Rasko; Michael Recht; Benjamin J Samelson-Jones; Amy MacDougall; Kristen Jaworski; Robert Noble; Marla Curran; Klaudia Kuranda; Federico Mingozzi; Tiffany Chang; Kathleen Z Reape; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2021-11-18       Impact factor: 91.245

4.  Application of in-vitro-cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action.

Authors:  Su Liu; Lisa Razon; Olivia Ritchie; Choong-Ryoul Sihn; Britta Handyside; Geoffrey Berguig; Jill Woloszynek; Lening Zhang; Paul Batty; David Lillicrap; Vishal Agrawal; Christa Cortesio; Kahsay Gebretsadik; Hassibullah Akeefe; Peter Colosi; Benjamin Kim; Stuart Bunting; Sylvia Fong
Journal:  Mol Ther Methods Clin Dev       Date:  2022-05-29       Impact factor: 5.849

5.  Defects in Protein Folding and/or Quality Control Cause Protein Aggregation in the Endoplasmic Reticulum.

Authors:  Juthakorn Poothong; Insook Jang; Randal J Kaufman
Journal:  Prog Mol Subcell Biol       Date:  2021

Review 6.  Current Clinical Applications of In Vivo Gene Therapy with AAVs.

Authors:  Jerry R Mendell; Samiah A Al-Zaidy; Louise R Rodino-Klapac; Kimberly Goodspeed; Steven J Gray; Christine N Kay; Sanford L Boye; Shannon E Boye; Lindsey A George; Stephanie Salabarria; Manuela Corti; Barry J Byrne; Jacques P Tremblay
Journal:  Mol Ther       Date:  2020-12-10       Impact factor: 11.454

Review 7.  Hemophilia Gene Therapy: Approaching the First Licensed Product.

Authors:  Paul Batty; David Lillicrap
Journal:  Hemasphere       Date:  2021-02-10

8.  Genetic Deletion of HLJ1 Does Not Affect Blood Coagulation in Mice.

Authors:  Man-Chen Hsu; Wei-Jia Luo; Bei-Chia Guo; Chia-Hui Chen; Po-An Hu; Yi-Hsuan Tsai; Kang-Yi Su; Tzong-Shyuan Lee
Journal:  Int J Mol Sci       Date:  2022-02-13       Impact factor: 5.923

Review 9.  Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury.

Authors:  Bénédicte Delire; Eleonora De Martin; Lucy Meunier; Dominique Larrey; Yves Horsmans
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

10.  Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability.

Authors:  Huriye Ercan; Lisa-Marie Mauracher; Ella Grilz; Lena Hell; Roland Hellinger; Johannes A Schmid; Florian Moik; Cihan Ay; Ingrid Pabinger; Maria Zellner
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.